EGFR and non-small cell lung carcinoma: The combination of osimertinib plus tepotinib, an oral, highly selective, potent MET tyrosine kinase inhibitor, is being assessed in the ongoing INSIGHT2 international, open-label, multicenter phase II trial in patients with advanced/metastatic EGFR-mutant NSCLC and acquired resistance to first-line osimertinib, and MET amplification determined centrally by FISH (gene copy number ≥ 5 and/or MET/CEP7 ≥ 2) at the time of progression.